PTJ
KPTI icon

Paul Tudor Jones’s Karyopharm Therapeutics KPTI Stock Holding History

Paul Tudor Jones’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,922
Closed -$95.1K – 3987
2025
Q4 		$95.1K Buy
+12,922
New +$79K ﹤0.01% 3384
2023
Q2 		– Sell
-10,082
Closed -$588K – 2701
2023
Q1 		$588K Buy
10,082
+2,098
+26% +$104K 0.01% 1524
2022
Q4 		$407K Buy
7,984
+3,980
+99% +$276K 0.01% 1721
2022
Q3 		$328K Buy
4,004
+370
+10% +$27.6K 0.01% 1722
2022
Q2 		$246K Buy
+3,634
New +$333K 0.01% 1690
2022
Q1 		– Sell
-13,902
Closed -$1.34M – 2373
2021
Q4 		$1.34M Buy
13,902
+1,040
+8% +$104K 0.02% 846
2021
Q3 		$1.12M Buy
12,862
+7,477
+139% +$776K 0.02% 1076
2021
Q2 		$834K Sell
5,385
-173
-3% -$25.1K 0.02% 937
2021
Q1 		$877K Buy
+5,558
New +$1.17M 0.02% 901
2020
Q4 		– Sell
-2,161
Closed -$473K – 1485
2020
Q3 		$473K Buy
+2,161
New +$529K 0.02% 835
2020
Q1 		– Sell
-3,591
Closed -$1.03M – 1196
2019
Q4 		$1.03M Buy
+3,591
New +$779K 0.05% 484
2018
Q2 		– Sell
-810
Closed -$163K – 1147
2018
Q1 		$163K Sell
810
-712
-47% -$142K 0.01% 893
2017
Q4 		$219K Buy
1,522
+317
+26% +$50.9K 0.01% 935
2017
Q3 		$198K Buy
1,205
+200
+20% +$28.6K 0.01% 964
2017
Q2 		$136K Buy
+1,005
New +$149K ﹤0.01% 935
2017
Q1 		– Sell
-775
Closed -$109K – 1470
2016
Q4 		$109K Sell
775
-313
-29% -$42.3K ﹤0.01% 1296
2016
Q3 		$159K Buy
+1,088
New +$131K ﹤0.01% 1292
2014
Q3 		– Sell
-1,000
Closed -$698K – 1425
2014
Q2 		$698K Buy
+1,000
New +$465K 0.03% 362

Other funds holding KPTI

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Paul Tudor Jones's KPTI Position: Q1 2026 in Review

Paul Tudor Jones sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 12,922 shares — an estimated $95.1K sold.

Paul Tudor Jones first reported a position in KPTI in Q2 2014 and held it in 18 quarters. The position peaked at $1.34M in Q4 2021. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Paul Tudor Jones reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 12,922 Karyopharm Therapeutics shares in Q1 2026, an estimated $95.1K.
  • Paul Tudor Jones first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 18 quarters.
  • Paul Tudor Jones's Karyopharm Therapeutics position peaked at $1.34M in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.